Japan has ended full reimbursement coverage for COVID-19 treatments, including antivirals, under its national health insurance (NHI) scheme and is planning to gradually increase patient co-payments to usual levels over the next six months.
Japan Ends Full Coverage For COVID Therapeutics, Pharma Braces For Price Cuts
Japan has started the stepped reduction of reimbursement of COVID-19 drugs under its national health insurance scheme, aiming to lower this to standard levels by April 2024. Oral antiviral Xocova also looks set to receive a one-off special price cut, over which the local industry has expressed its concerns.
More from Japan
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
Japan recommends eight new drugs for approval, including two for cardiomyopathy, and will also raise prices for multiple products, including Enhertu, on 1 April.
• By
A plan to reduce benefits under Japan's financial safety net for patients contributing to the costs of their long-term medical care is being reconsidered by the government following protests from patient and doctor groups.